alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 71 studies with an author at Michigan Medicine (US) · free to read (page 2 of 3) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 71 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Annals of neurology 2001-09-01

Seeking antemortem markers to distinguish Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), we examined brain glucose metabolism of DLB and AD. 5 key findings →

Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-01-01

Positron emission tomography (PET) of brain amyloid b is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognability: An Ecological Theory of neighborhoods and cognitive aging

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Social science & medicine (1982) 2022-07-20

While a growing body of evidence points to potentially modifiable individual risk factors for dementia, the built and social environments in which people develop and navigate cognitive decline are largely overlooked. 2 key findings →

Participants: 21,151 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-01-01

This article focuses on the effects of operational differences in case ascertainment on estimates of prevalence and incidence of cognitive impairment and/or dementia of the Alzheimer type. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Dementia incidence among a cohort of lebanese older adults: first incidence estimates from the Middle East and North Africa region

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Frontiers in Dementia 2025-01-07

After 3.5 years of follow up, 19 new cases of dementia were identified among 229 surviving participants. 5 key findings →

Design: cohort study Participants: 341 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Annals of neurology 2012-04-01

Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely understood. 4 key findings →

Participants: 35 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Racial/Ethnic Disparities in Hospital Readmission and Frequent Hospitalizations Among Medicare Beneficiaries With Alzheimer’s Disease and Related Dementia: Traditional Medicare Versus Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 54 out of 100. The Journals of Gerontology Series B 2024-05-10

TM was associated with higher odds of 30-day readmission (OR = 1.07 [CI: 1.02 to 1.12]) and frequent hospitalizations (OR = 1.10 [CI: 1.06 to 1.14]) compared to MA. 5 key findings →

Design: case-control study Participants: 36,656 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Consistency of a Dementia Diagnosis Between Systems for Patients Receiving Care Through the VA, Traditional Medicare, and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Medical Care 2026-06-04

For VA and Medicare cohorts, dementia diagnosis was absent in 88.7% and 80.5%, respectively, of follow-up encounters in the other system. 5 key findings →

Design: cohort study Participants: 68,092 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The American journal of medicine 2017-01-05

A clinical tool can be used to predict 30-day mortality in patients hospitalized with lower gastrointestinal bleeding. 2 key findings →

Participants: 4,044 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Geographic Variation in Neurologist Density and Neurologic Care in the United States

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurology 2020-12-23

Mean density of neurologists varied nearly 4-fold from the lowest to the highest density quintile (9.7 [95% confidence interval (CI) 9.2-10.2] vs 43.1 [95% CI 37.6-48.5] per 100,000 Medicare beneficiaries). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Annals of neurology 1997-06-01

We held an international consensus conference on frontotemporal dementia, behavioral disturbances, and parkinsonism linked to chromosome 17 to determine whether these are homogeneous or heterogeneous disorders, to agree on terminology, and to develop strategies for further research. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The measurement of cognition in large-scale cross-national surveys: lessons from the Health and Retirement Study International Network of Studies and the Harmonized Cognitive Assessment Protocol

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Journals of Gerontology Series B 2025-10-16

These lessons emphasize the importance of ensuring tests are feasible across both high-income countries and LMICs, maintaining consistency within studies and over time, and designing comprehensive cognitive batteries for improved measurement precision of general and domain-specific phenotypes. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Neighborhood‐Level Disadvantage with Antemortem MRI Brain Volumes in a Multi‐site Brain Bank Donor Cohort

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer s & Dementia 2025-12-01

A significant ADI × dementia interaction was observed for global atrophy (p = .005) and several other outcomes. 5 key findings →

Design: longitudinal study Participants: 14 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials

✓ Peer-reviewed alzhub usefulness score 49 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2008-06-12

Among mild to moderate AD patients, enrolled in an actual clinical trial, these results suggest evidence based guidelines for using the MacCAT-CR understanding subscale to help guide judgments about whether a patient has the capacity to consent. 3 key findings →

Design: cross-sectional Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Reducing between scanner differences in multi-center PET studies

✓ Peer-reviewed alzhub usefulness score 49 out of 100. NeuroImage 2009-02-06

This work is part of the multi-center Alzheimer's Disease Neuroimaging Initiative (ADNI), a large multi-site study of dementia, including patients having mild cognitive impairment (MCI), probable Alzheimer's disease (AD), as well as healthy elderly controls. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-07-01

Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Science translational medicine 2024-03-13

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is an advanced stage of metabolic fatty liver disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mortality and Discharge Location of Intensive Care Patients With Alzheimer Disease and Related Dementia

✓ Peer-reviewed alzhub usefulness score 47 out of 100. American Journal of Critical Care 2023-06-30

A total of 145 342 adults met inclusion criteria; 10.5% had ADRD and were likely to be older, female, and have more comorbid conditions. 4 key findings →

Participants: 342 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events